Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;6(Suppl 1):S58-S61.
doi: 10.21037/tlcr.2017.10.09.

Raising the bar: the future of EGFR inhibition in non-small lung cancer

Amanda J Redig  1   2   3
Affiliations
Editorial

Raising the bar: the future of EGFR inhibition in non-small lung cancer

Amanda J Redig. Transl Lung Cancer Res. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: AJ Redig has received consulting fees from Medtronic, Boehringer-Ingelheim, Ariad, Roche, and AstraZeneca and a sponsored research agreement with AstraZeneca.

Comment on

References

    1. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 2016;10:113-29. 10.1177/1753465815617871 - DOI - PMC - PubMed
    1. Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99. 10.1056/NEJMoa1411817 - DOI - PubMed
    1. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016;17:234-42. 10.1016/S1470-2045(15)00488-X - DOI - PMC - PubMed
    1. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97. 10.1056/NEJMoa1311107 - DOI - PMC - PubMed
    1. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73. 10.1371/journal.pmed.0020073 - DOI - PMC - PubMed